Information on how to access Mylotarg™▼ (gemtuzumab ozogamicin) and cytarabine prescribing information and adverse event reporting can be found at the bottom of the page.
Additional Administration Information
- MYLOTARG must not be used during pregnancy unless the potential benefit to the mother outweighs the potential risks to the foetus. Women or partners of women with childbearing potential should use two methods of contraception during treatment and for at least 7 months (females) or 4 months (males) after the last dose.
- Female patients should avoid breast feeding while receiving MYLOTARG and for ≥ 1 month after the final dose
- Before administering each dose of MYLOTARG, complete blood counts should be assessed, as well as baseline liver function tests (ALT, AST, total bilirubin and ALP levels) to monitor for hepatotoxicity, including VOD
- Premedication with a corticosteroid, antihistamine and paracetamol is recommended 1 hour prior to MYLOTARG dosing to ameliorate infusion-related reactions
- MYLOTARG is light sensitive and should be protected from UV light during reconstitution, dilution and administration
- Following reconstitution and dilution, MYLOTARG should be administered by IV infusion over a 2-hour period and should not be administered as an IV push or bolus
- Infusion of MYLOTARG should be performed under close clinical monitoring, including pulse rate, blood pressure and temperature
- Patients receiving MYLOTARG should be monitored for clinical signs and symptoms of infection, bleeding/haemorrhage, or other effects of myelosuppression and tumour lysis syndrome. Additionally, due to the risk of VOD/SOS, signs and symptoms of VOD/SOS should be closely monitored; these may include elevations in ALT, AST, total bilirubin, and alkaline phosphatase, which should be monitored prior to each dose of MYLOTARG, hepatomegaly (which may be painful), rapid weight gain, and ascites. Monitoring only total bilirubin may not identify all patients at risk of VOD/SOS. For patients who develop abnormal liver tests, more frequent monitoring of liver tests and clinical signs and symptoms of hepatotoxicity is recommended
- Once cytogenetic testing results are available, consider the risk-benefit of continuing treatment with MYLOTARG; the efficacy of MYLOTARG has been demonstrated in AML patients with favourable- and intermediate-risk cytogenetics, but not in patients with adverse cytogenetics
Please view MYLOTARG SmPC for more information
Explore more
Pharmacy Guide
Download the Pharmacy booklet which is a guide to treatment with MYLOTARG. SmPC should be consulted for full guidance.
Download Pharmacy Guide
Fast Facts
Download the fast facts PDF document to aid your understanding of MYLOTARG
View Fast Facts PDF
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AML, acute myeloid leukaemia; ANC, absolute neutrophil count; AST, aspartate aminotransferase; IV, intravenous; SmPC, Summary of Product Characteristics; UV, ultraviolet; VOD, veno-occlusive disease.
- MYLOTARG Summary of Marketing Product Characteristics.
For further details on dosing and schedule
Dosing Guide
For UK Healthcare Professionals*
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020
No